Amlodipine/irbesartan - Sanofi

Drug Profile

Amlodipine/irbesartan - Sanofi

Alternative Names: Aimix Combination Tablets HD; Aimix Combination Tablets LD; Amlodipine besilate/irbesartan; Aprovasc; DSP-8153; Irbesartan/amlodipine; Irbesartan/amlodipine besilate

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; Sumitomo Dainippon Pharma
  • Class Antihypertensives; Biphenyl compounds; Dihydropyridines; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 18 Mar 2015 No recent reports of development identified - Phase-II for Hypertension in South Korea, Philippines, Taiwan and India (PO)
  • 17 Mar 2015 Launched for Hypertension (Treatment-experienced) in Japan, Argentina and Lebanon (PO) before March 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top